Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. - Wikidata - wikimedia - TriplyDB

Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease.

Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease.

http://www.wikidata.org/entity/Q35108913

about

Uric acid in metabolic syndrome: From an innocent bystander to a central player Mitochondria: a new therapeutic target in chronic kidney disease Uric Acid as a Marker of Kidney Disease: Review of the Current Literature Uric Acid is independently associated with diabetic kidney disease: a cross-sectional study in a Chinese population Allopurinol therapy improves vascular endothelial function in subjects at risk for cardiovascular diseases: a meta-analysis of randomized controlled trials.Early onset hyperuricemia is a prognostic marker for kidney graft failure: Propensity score matching analysis in a Korean multicenter cohort.Association between allopurinol and mortality among Japanese hemodialysis patients: results from the DOPPS.Is reversal of endothelial dysfunction still an attractive target in modern cardiology?Allopurinol is an independent determinant of improved arterial stiffness in chronic kidney disease: a cross-sectional study.Xanthine oxidoreductase regulates macrophage IL1β secretion upon NLRP3 inflammasome activation.Uric acid as a mediator of diabetic nephropathy.Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis.Effects of Allopurinol on Arterial Stiffness: A Meta-Analysis of Randomized Controlled Trials Allopurinol and the risk of stroke in older adults receiving medicare Uric Acid as a Marker of Mortality and Morbidity in Fabry Disease.The role of pulmonary arterial stiffness in COPD.Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes.Cardiovascular Effects of Unilateral Nephrectomy in Living Kidney Donors.Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease.Gender-related differences in the association between serum uric acid and left ventricular mass index in patients with obstructive hypertrophic cardiomyopathy.Association of Endothelial and Mild Renal Dysfunction With the Severity of Left Ventricular Hypertrophy in Hypertensive Patients.Uric acid and chronic kidney disease: A time to act?Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study.Allopurinol reduces the risk of myocardial infarction (MI) in the elderly: a study of Medicare claims.A Randomized Controlled Trial of the Effects of Febuxostat Therapy on Adipokines and Markers of Kidney Fibrosis in Asymptomatic Hyperuricemic Patients With Diabetic Nephropathy.New insights into uric acid effects on the progression and prognosis of chronic kidney disease.The role of uric acid in the pathogenesis of human cardiovascular disease.Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis.Urate reduction and renal preservation: what is the evidence?Mitochondrial dysfunction in the pathophysiology of renal diseases.Sudden cardiac death in haemodialysis patients: preventative options.Future Treatment of Hypertension: Shifting the Focus from Blood Pressure Lowering to Arterial Stiffness Modulation?An Update on Intradialytic Cardiac Dysfunction.Management of Gout and Hyperuricemia in CKD.Long-Term Non-End-Stage Renal Disease Risks After Living Kidney Donation.A perspective on chronic kidney disease progression.Resistant hypertension in nondialysis chronic kidney disease.Treatment of asymptomatic hyperuricemia in chronic kidney disease: A new target in an old enemy - A review.Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial.Nitroso-redox imbalance affects cardiac structure and function.

P2860

Q26772053-2AAFEBF8-C3CE-4C53-B72B-A9E5862D727F Q26776397-5BBA44E6-5557-4833-93A3-963D6A6DF14D Q26849588-3CCF2113-CF74-4C66-99A6-0BA91E18D4B9 Q28547672-16371242-F90F-493A-8E31-8DBD3C28AF12 Q30248398-F1F5B3C1-920F-4B99-AA4E-6AAF25CD3314 Q33632726-412E257E-0679-42CF-A65C-C6DDC241E9DD Q34100586-A49044C3-C93D-4E4D-8873-320EB98A5624 Q34179077-58A55878-C02C-4E3F-933F-3F5030FEF38C Q35121532-CF8DF570-B2BB-4AED-9AA8-FF00F3521073 Q35247002-3D4A31CD-E6A9-4663-B3CF-03DD2842A479 Q35393446-168AF898-C367-4E2E-92E3-A49CDFA4DED7 Q35605560-871B5087-8600-4EF3-99A9-20CB5D72F7B8 Q35998065-EEB3C443-A114-49AA-86F4-E01C00157220 Q36125528-60E48371-1541-4596-A7A2-B3A679DA36CE Q36189989-5AE48442-C775-4C50-9D73-AB7F9ECD466A Q36284886-758D6AEF-5266-4E30-BB57-E9A1A651A1EE Q36306524-1D2EA2BE-37DB-460B-B77D-213C5D753733 Q36472396-9CB52957-837B-4980-819C-EF6160A69EEF Q36741005-E0597F30-ED5C-42DC-B274-9FB9816CAB3F Q36769535-33590CFA-4F4C-4D05-8B8C-7C2814BDCC98 Q36950146-E7781812-2765-4321-BC31-75D8B84B6E04 Q37195441-0F587617-E122-4721-B86E-1D3B07E8261B Q37251800-30799F92-BB1D-4A44-B286-F47A8C48C687 Q37274458-7D3B0305-0F06-4674-BE63-0EC20DF858B3 Q37674565-C05B6790-80FC-499E-8690-FC3227B2FF2F Q37977142-FE01F2FA-E0F7-4607-AC6A-CF2F3BCCC07F Q38076242-C500B975-2B49-4A15-9BD5-8F591E196446 Q38138322-84289795-414A-462D-977A-3C4897AF3305 Q38160768-CD5D74DA-8358-4364-ABBC-8DA9F1AD83CF Q38168664-50AEEE33-B06F-4DEC-8FF9-CD1FDD07E6D1 Q38250885-D7ABB60A-C5A4-4324-AE62-F2C24C190EE5 Q38544207-33B9BAAF-75A9-4C23-B693-8BD82F198C8D Q38807482-217CD44F-8792-491D-B794-863C827DC353 Q38812962-8CFF611C-83D0-45CC-A5A6-FA0A30B96FE2 Q38928790-8414A7C1-FF86-46B9-B817-FC8EC6C3E47C Q39038570-DF7F31F6-7B54-4B53-8063-5ABBFEFE3474 Q40716454-6D0B70B2-C12A-473B-8DFE-C97701DBB6EB Q41026351-490620A6-AE5D-408C-B329-3FE275BACB79 Q41026359-6993BFF9-C526-4B9A-8F6D-9D52BF3B44A4 Q42668752-C4520C9D-7A7E-4B7C-9008-6AECEDD6113D

P2860

Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease.

http://www.wikidata.org/entity/Q35108913

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Allopurinol benefits left vent ...... ion in chronic kidney disease.

@ast

Allopurinol benefits left vent ...... ion in chronic kidney disease.

@en

type

label

Allopurinol benefits left vent ...... ion in chronic kidney disease.

@ast

Allopurinol benefits left vent ...... ion in chronic kidney disease.

@en

prefLabel

Allopurinol benefits left vent ...... ion in chronic kidney disease.

@ast

Allopurinol benefits left vent ...... ion in chronic kidney disease.

@en

P1433

Q35108913-4539933C-268F-46E4-A742-B736E8C5E5E0

P1476

Q35108913-801EB2A2-9AF9-48CD-B671-6DB0CC7FC5CF

P2093

Q35108913-055AAD49-A4CF-4C44-8E0D-076CA031510F

Q35108913-2A850AD2-67EB-40DD-B9F8-F3B61EEDA33F

Q35108913-55EAD356-DB64-4CFB-B43E-447D8B367737

Q35108913-C46706FF-86F2-4ABB-AF4C-EB0A98C6DE2C

Q35108913-C579F21A-168D-4695-BCBC-6CC0DDF281A9

P2860

Q35108913-0908B1F4-F66C-46F3-AEF8-EA03BBCE590E

Q35108913-09939E15-D8F2-48FA-8C05-ACB57CA40700

Q35108913-216D6859-680D-48C3-A2E0-522D292A43EF

Q35108913-2430E3EA-3CD8-4E70-BDB2-9783895434EA

Q35108913-3E742C62-B297-41A4-8038-5B74BE250848

Q35108913-41DAD22E-F3E1-465A-875C-4D371038B23B

Q35108913-466CF014-AFBC-434F-A5F7-38D3614A3D31

Q35108913-64C211A4-EDCF-4EC2-8E5F-AF16963B96E7

Q35108913-664AC769-6336-4C6A-BF86-E3C6F8ECC795

Q35108913-70707F19-E909-4D9A-90DB-FB23BDDD2AEE

P304

Q35108913-7F42F389-FD2D-423B-9EFF-B022A92CCC2A

P31

Q35108913-888DFCAF-5A09-48B0-B38F-2256CA7A4025

P356

Q35108913-8F3FEA22-C220-4CBF-B7DB-13ED6A7077B8

P433

Q35108913-670707E1-1293-44A8-BABF-D7E90FF1E648

P478

Q35108913-219F770E-3D89-4418-B812-C05FD624F115

P50

Q35108913-7FA3369C-5DE1-49C3-844A-8E0AD1E7C736

Q35108913-E9AF1BB4-6121-411D-A76D-096E73439149

P577

Q35108913-294767B4-381E-4FF6-A46F-FF0E25BF03AC

P698

Q35108913-FC46D14D-B990-4830-8D6B-9A99F2B1B787

P921

Q35108913-6531502A-CA5E-4FE2-883F-666D67C66850

P932

Q35108913-94C2E20E-05E6-48AD-846D-D0E06A6341BC

P356

P1433

Journal of the American Society of Nephrology

P1476

Allopurinol benefits left vent ...... ion in chronic kidney disease.

@en

P2093

Donald S Ang

http://www.w3.org/2001/XMLSchema#string

J Graeme Houston

http://www.w3.org/2001/XMLSchema#string

M Adnan Nadir

http://www.w3.org/2001/XMLSchema#string

Michelle P Kao

http://www.w3.org/2001/XMLSchema#string

Stephen J Gandy

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of allopurinol in chronic kidney disease progression and cardiovascular risk

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.

High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid.

Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study

Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice

Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force

Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.

Association between allopurinol and mortality in heart failure patients: a long-term follow-up study.

Clinical epidemiology of cardiovascular disease in chronic renal disease.

P304

1382-1389

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2010111185

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Allan D. Struthers

P577

2011-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21719783

http://www.w3.org/2001/XMLSchema#string

P921

P932

3137586

http://www.w3.org/2001/XMLSchema#string